Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

173 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-10-31

Study Completion Date

2008-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the groups with respect to influenza immune responses following Dose 1 of Fluzone vaccine (2006-2007 formulation).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine

NCT00831987

Influenza

COMPLETED PHASE4

Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age

NCT00858468

Influenza

COMPLETED PHASE1/PHASE2

Study of Safety and Immunogenicity of Fluzone® in Healthy Children

NCT00831675

Influenza

COMPLETED PHASE4

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)

NCT01691326

Influenza

COMPLETED PHASE4

Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®

NCT00836953

Influenza

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fluzone®-Primed Group

Participants had received two doses of the 2005-2006 formulation of Fluzone® vaccine in the fall of 2005 (Study GRC28, NCT00242424), will receive 2 doses of Fluzone® Pediatric 2006-2007 formulation.

Group Type EXPERIMENTAL

Influenza Virus Vaccine, Fluzone®

Intervention Type BIOLOGICAL

0.25 mL, Intramuscular

Fluzone®-Naive Group

Participants had never received Influenza vaccine and had received two doses of placebo in the fall of 2005 (Study GRC28, NCT00242424), will receive 2 doses of Fluzone® Pediatric 2006-2007 formulation.

Group Type EXPERIMENTAL

Influenza Virus Vaccine, Fluzone®

Intervention Type BIOLOGICAL

0.25 mL, Intramuscular

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Influenza Virus Vaccine, Fluzone®

0.25 mL, Intramuscular

Intervention Type BIOLOGICAL

Influenza Virus Vaccine, Fluzone®

0.25 mL, Intramuscular

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fluzone® Fluzone®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Previously enrolled in study GRC28 and received 2 vaccinations of the assigned lot.
* Considered to be in good health on the basis of reported medical history and history-directed physical evaluation.
* Available for the duration of the study.
* Parent/legal representative willing and able to provide informed consent.
* Parent/legal representative able to attend all scheduled visits and comply with all trial procedures.
* Parent/legal representative willing to permit venipuncture for purposes of collecting a blood sample.

Exclusion Criteria

* Receipt of any vaccine within the past 7 days (subjects may be deferred until after the seven days has passed.)
* Reported allergy to egg proteins, chicken proteins or any other constituent of the vaccine.
* Ever received any influenza vaccine, other than at Visits 1 and 2 of study GRC28, or known to have ever been diagnosed with laboratory-confirmed influenza.
* An acute illness with fever (rectal temperature ≥ 100.4°F \[38.0°C\]) in the 72 hours preceding enrollment in the trial (defer enrollment).
* Known bleeding disorder.
* Participation in any other interventional clinical trial within 30 days prior to enrollment, or planned participation in another interventional clinical trial prior to termination of the subject's participation in the study.
* Known or suspected impairment of immunologic function or receipt of immunosuppressive therapy or immunoglobulin since birth.
* Personal or immediate family history of congenital immune deficiency.
* Developmental delay, neurologic disorder, or seizure disorder.
* Chronic medical, congenital, or developmental disorder that, in the opinion of the investigator, could interfere with trial conduct or completion.
* Known Human Immunodeficiency Virus (HIV)-positive mother or Hepatitis B surface antigen (HBsAg)-positive mother.
* Known HIV, Hepatitis B, or Hepatitis C infection.
* Administration of immune globulin or other blood products within the last three months, or injected or oral corticosteroids or other immunomodulator therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting \< 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment.
* Prior personal history of Guillain-Barré syndrome.
* Any condition that, in the opinion of the investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine.

Minimum Eligible Age

11 Months

Maximum Eligible Age

14 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes